It may be a bit of corporate puff, but why not when your device has crept up on a significant milestone? In this case, medical surface technologist Titan Spine, developer of innovative spinal interbody fusion implants, says it has reached 18,000 implantations of its Endoskeleton® interbody fusion devices since its inception. The company’s approaching a $20 million annualized sales revenue run-rate, suggesting its getting its message across about the benefits of devices incorporating its roughened titanium surface technology.
The full line of Endoskeleton® devices features Titan Spine’s proprietary implant surface technology, consisting of a unique combination of roughened topographies at the macro, micro, and cellular levels. The combination of surface levels is designed to create an optimal host-bone response and actively participate in the fusion process by promoting new bone growth, encouraging natural production of bone morphogenetic proteins (BMPs) and creating the potential for a faster and more robust fusion.
We’ve followed the company extensively over the last several years, notably covering its Endoskeleton TT transforaminal lumbar interbody fusion (TLIF) device launch back in 2009. Now the company is boasting more than 5,300 implants per year, over 150 surgeon customers, over 60 US distributors and a remarkable 40% year-on-year revenue growth for its most recently reported period (9 months to end of September 2013).
And last week Titan Spine announced a distribution deal with Biomet in Germany, which is likely to accelerate growth in that country as well as form the foundations for European revenue growth.
Kade Huntsman, M.D., Orthopedic Spine Surgeon with the Salt Lake Orthopaedic Clinic in Salt Lake City, Utah, states, “One of the reasons that I believe Titan Spine’s interbody devices have resonated well with surgeons is because of the strength and design of the implant combined with the cell signaling properties of its surface technology. I like that its roughened surface technology is created from a reductive process and does not possess a coating that could have the potential for delamination or degradation. I feel very confident implanting Titan’s Endoskeleton® devices and am pleased to include them in my practice.”
Kevin Gemas, President of Titan Spine, commented, “We are encouraged to see several other companies that are adopting the Titan Spine approach by launching interbody devices with roughened surfaces and beginning to acknowledge shortcomings with their standard PEEK and smooth titanium offerings. We have been optimizing our surface technology and its bone formation effects for the past six years through collaboration with thought leaders in materials science and biomedical engineering and feel that our commitment to be the leaders in surface technology is the reason we are starting to see rapid acceleration in our sales growth.”
Source: Titan Spine, LLC., Business Wire